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Abstract
Polymyalgia rheumatica and giant cell arteritis are relatively common, but under research inflammatory rheumato-
logical conditions. This survey aimed to ascertain the matters in which patients feel they need support with these
conditions and appraise how the Charity PMRGCAuk currently supports these needs and could do so in the future.
PMRGCAuk members (n = 910) were invited to complete an on-line survey. The survey requested the respondent’s
history of PMR and or GCA, their perceived priorities for support for people with PMR and or GCA and views on
the services already provided by the Charity. A total of 209 people completed the survey. Less than 24% had heard
of either PMR or GCA before their diagnosis. Priorities in supporting people with PMR and or GCA included: being
on and tapering off glucocorticoids (76.6%), specifically, length of treatment and the risks versus benefits and
managing side effects. Respondents generally reported satisfaction with the services currently provided by
PMRGCAuk. The support provided by PMRGCAuk is very helpful to members and fills an important gap in
provision for people with PMR and or GCA. The areas in which the greatest proportions of participants requested
support do not have an evidence base to underpin them. It is incumbent on the research community to address
patients’ concerns and provide an evidence base where it is required by those affected.
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Introduction
Polymyalgia rheumatica (PMR) and giant cell arteritis
(GCA) are closely associated inflammatory rheumato-
logical conditions affecting older people. PMR can
cause pain and stiffness in the shoulders and hip girdles,
whilst GCA classically presents with a headache, scalp
tenderness and sometimes jaw or tongue claudication
and can, if not treated, cause irreversible blindness.
Both conditions are usually accompanied by raised in-
flammatory markers (e.g. ESR, CRP) and can also occur
with systemic symptoms such as fever, unintentional
weight loss and fatigue [1]. PMR and GCA commonly
co-exist and are often thought of as being part of a
disease spectrum. Estimates vary, but 16 to 21% of
those with PMR will go on to develop GCA, whilst
40 to 60% of those with GCA will also have symptoms
of PMR during their illness [2].
Although relatively common, with a lifetime preva-
lence of 2.4% in women and 1.7% in men [3], PMR
has received little research attention, particularly in the
primary care setting, where over 80% of patients are
exclusively diagnosed and managed [4]. Currently, the
recommended first-line treatment for PMR in interna-
tional guidelines remains medium- to low-dose oral glu-
cocorticoids, which are not always popular with patients
[5]. Other treatments for refractory disease and those
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with an intolerance to glucocorticoids have been sug-
gested (e.g. methotrexate, tocilizumab) [6, 7], but the
evidence for these is still limited.
Although less common than PMR, GCA has potentially
serious complications (e.g. irreversible sight loss if left un-
treated) and requires higher doses of glucocorticoids for suc-
cessful treatment. There has recently been a trial of toci-
lizumab as a glucocorticoid sparing agent in GCA [8],
prompting guidance from the National Institute for Health
and Care Excellence in the UK [9].
In order to support people with PMR and GCA, the charity
PMRGCAuk was formed in 2010 after a group of patients
contacted each other via an Internet forum. It now has over
900 members, with others having signed up via the website to
receive regular newsletters. The charity provides invaluable
education, advice and peer support to those people with
PMR and/or GCA and their carers. This fills an important
gap where research evidence is limited and pragmatic advice,
through traditional medical routes, on living with PMR and or
GCA and managing its treatment is lacking. Support is avail-
able via four main routes: local support group meetings, a
telephone helpl ine, a web forum (hosted by the
HealthUnlockedwebsite [10]) and the charity’s own dedicated
website. The Charity also produces a regular newsletter, called
NewsWire. NewsWire details recent and upcoming events, as
well as new developments in health services and research for
PMR and GCA.
In the spring/summer of 2017, PMRGCAuk conducted a
survey of its membership and other interested parties known
to the charity and receiving regular updates from them. The
aims of this survey were to understand more fully the prior-
ities of their membership in terms for support for living with
PMR and or GCA, to evaluate the services provided by the
charity and the impact they were having, and to provide an
opportunity for interested parties to suggest improvements
to their services. In this paper, we summarise the results of
the survey and its potential implications for the rheumatol-
ogy research community.
Methods
Study design
The cross-sectional survey of 13 questions was conducted by
PMRGCAuk using SurveyMonkey.com. A link to the survey
was emailed to all members (n = 910) and other contacts on
the charity mailing list with a valid email address in April
2017. The survey was also advertised in the NewsWire
newsletter, which was sent by post to all members in the
same month, and via the Charity’s website and social media
outlets including Facebook, Twitter and the HealthUnlocked
forum [10]. Potential participants were also able to contact the
Charity to ask for paper copies of the questionnaire to be sent
in the post and responses were entered manually into
SurveyMonkey on their return to the Charity’s office. The
survey was closed at the end of July 2017.
As this was a service evaluation conducted by the Charity,
ethical approvals were not required.
Data collection
The survey collected information in three broad areas, as
outlined below.
Background information on PMR/GCA
Survey participants were asked to indicate whether they had
PMR, GCA, both or had recovered from their condition.
Where these responses were not applicable, a text box was
available for the respondent to give their chosen response.
They were also asked how long ago they were diagnosed,
whether they had heard of PMR and or GCA before they
received their diagnosis and how they had become aware of
the Charity.
Priorities for supporting people with PMR and GCA
Respondents were asked in the survey to choose up to five of
14 pre-defined aspects of supporting people with PMR and or
GCA that they felt were most important. One of these options
was Bbeing on and tapering off steroids^. Respondents who
chose this option were then asked to complete a further item to
provide more detail on their response. This additional detail
was added after treatment with glucocorticoids was
established as a major concern for the Charity’s members in
a previous survey [5].
Satisfaction with services provided by the Charity
Participants were asked to consider their use of each of the
avenues of support provided by the Charity (local groups,
helpline, forum, website) and to rate their agreement with
various statements regarding each form of support on a four-
point Likert scale (strongly disagree, disagree, agree, strongly
agree), with a fifth option of Bdon’t know/not applicable^. For
each of the avenues of support, there was also a free text
option to invite respondents to comment on how the service
provided by the Charity could be improved.
In addition, this section contained items asking re-
spondents if they did not attend a support group meet-
ing, what their reasons were for not attending and asked
would they like to join a telephone support group if one
were available. There were also specific questions re-
garding use of the telephone helpline.
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Data analysis
For the purpose of analysis, the Likert scales were categorised
to ‘Agree’ (strongly agree, agree) versus ‘Disagree’ (disagree,
strongly disagree). BDon’t know/not applicable^ was treated
as missing, because these respondents did not express an opin-
ion. Closed questions were analysed using frequencies and
percentages. For items relating to current status of the respon-
dents PMR and or GCA, how they found out about
PMRGCAuk and why they do not attend a support group in
person, where possible the responses in the text box were
transposed into the pre-defined response options. Where this
was not possible, the additional responses are noted in the
footnotes to the tables.
Data from the text boxes relating to how each avenue of
support could be improved were analysed independently by
two researchers (SM, CAH) to identify recurring themes.
Data availability All data generated or analysed during this
study are included in this published article [and its supplemen-
tary information files].
Results
A total of 209 surveys were completed: 206 online via
SurveyMonkey and three via printed versions of the question-
naire. The majority of respondents reported having PMR (n =
120, 57.4%), whilst approximately equal numbers reported
having GCA, both conditions or being a recovered patient
(Table 1). A total of 4.8% (n = 10) reported their condition
having started in the previous 3 months and 20.3% (n = 42)
between 3 and 12 months prior to response. A fifth of respon-
dents reported the time since diagnosis as more than 5 years
(n = 41, 19.8%). Less than a quarter of people reported having
heard of PMR or GCA before their diagnosis (n = 48, 23.3%).
The majority of people reported having found out about the
Charity through an Internet search (n = 110, 64.7%). A fifth
were told about it by a doctor (n = 45, 26.5%). The next largest
groups were those reading about the group in a magazine/
newspaper, or being told by word-of-mouth, which was not
an option on the survey, but frequently given as a response in
the accompanying free text item.
The priority for supporting people with PMR and or GCA
most often chosen as important by respondents was Bbeing on
and tapering off steroids^ (n = 160, 76.6%) (Table 2). The
aspect of glucocorticoid treatment that respondents were most
concerned about was the tapering of the dose, with over 90%
(n = 145) of people identifying this as an issue. A total of 63%
(n = 101) wanted information on the duration of treatment
with over 61% of people (n = 99) endorsing items relating to
benefits and side effects of treatment and how to manage side
effects. The need for information on how to take steroids was
less widely requested (n = 56, 35.0%).
Approximately half of patients reported Bmanaging fatigue
and debilitation^ and Bknowing whether what is happening to
me is ‘normal’^ to be important. New research (n = 95,
45.5%) and the outlook for recovery (n = 83, 39.7%) were
the next two most highly prioritised aspects. With the excep-
tion of diet and nutrition (13.4%) and work and employment
(2.4%), all aspects of which the survey enquired were en-
dorsed by at least 20% of respondents.
Respondents were generally very positive about support
provided by the Charity (Table 3). However, 25.7% of people
(n = 27) reported being confused by other people’s responses
on the HealthUnlocked forum. Additional suggestions for the
support groups included trying to boost attendance at meet-
ings, having more structure/national input and external
speakers. Also, comments were made regarding the website
to improve user-friendliness, especially on a tablet/mobile de-
vice, which was targeted as a point for improvement. For the
helpline, there was a suggestion to have an alternative for
those who cannot use a telephone (e.g. hearing impairment).
Across the local group meetings, forum and website, there
Table 1 Characteristics of respondents
n (%)
PMR/GCA status
Have PMR 120 (57.4)
Have GCA 32 (15.3)
Have PMR and GCA 30 (14.4)
Recovered patient (either condition) 21 (10.1)
Othera 6 (2.9)
Time since diagnosis
> 5 years 41 (19.8)
3–5 years 39 (18.8)
2–3 years 41 (19.8)
1–2 years 34 (16.4)
3–12 months 42 (20.3)
< 3 months 10 (4.8)
Had heard of PMR/GCA before diagnosis 48 (23.3)
First became aware of PMRGCAuk
Reading magazine/newspaper 8 (4.7)
Poster 2 (1.1)
Internet search 110 (64.7)
Doctor 45 (26.5)
Calling a helpline 1 (0.6)
Facebook/Twitter 0 (0.0)
Local support group 3 (1.8)
NewsWireb magazine 1 (0.6)
Conference/exhibition 0 (0.0)
a Includes 5 people where diagnosis is unclear/changed from PMR/GCA
and 1 carer
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were suggestions that PMR and GCA should be more sepa-
rated, as GCA appears not to get the same ‘coverage’ as PMR.
The majority of people, who did not attend a local support
group, did not do so because there was not one close by (n =
63, 64.3%) (Table 4). However, there was some interest in the
idea of a telephone support group, with 43.3% of those
responding to the question (n = 81) reporting that they might
join if one were available.
Discussion
Discussion
This survey has provided contemporary insights into the areas
in which members of a PMR and GCA support charity think
support and further research are important. These areas were
broadly around management and prognosis. It also identified
that members of PMRGCAuk are largely very satisfied with
the support they receive from the Charity.
At the time of the survey, membership of PMRGCAuk
was approximately 910, but the survey was also sent to
other contacts of the Charity who were not members and
there is the possibility that the survey may have reached
other people as well. Hence, there is no denominator pop-
ulation against which to compare survey responders.
However, we do not expect the reach to be large, as this
is a relatively small patient community. Furthermore, the
Charity did not request demographic information in the
survey, and so, the respondents cannot be compared to a
‘classical’ PMR or GCA population. However, whether or
not the sample is in any way ‘representative’ is largely
irrelevant for the purposes of this paper and indeed in-
cludes one person who was a carer, rather than patient
or former patient. It would seem unlikely that the survey
has been completed by anyone who does not have an
interest in either or both of the conditions, and the focus
was to recognise what is important to a range of people
with an interest in the conditions and to understand
whether the charity is fulfilling its objectives. In this set-
ting, the engagement of interested parties is seen by advi-
sory groups, such as INVOLVE, as more important than
representativeness [11]. Results from this survey give an
insight into the opinions of those who seek help in man-
aging these conditions over and above what has been of-
fered by their usual health services. The completion of the
survey by at least one person who reported themselves to
be a carer is important for the Charity, who suspect that
this is a growing group of people that needs their support.
It should also therefore be a relevant group of people for
clinicians, as they work with friends and relatives in car-
ing for patients.
As populations age and the number of health condi-
tions to be managed grows, collaboration between formal
Table 2 Important aspects in
supporting people with PMR/
GCA
n (%)
Being on and tapering off steroids 160 (76.6)
Information on additional/alternative medication (e.g. pain relief, methotrexate) 60 (28.7)
Outlook for recovery 83 (39.7)
Sight loss caused by undiagnosed GCA 58 (27.8)
Managing pain 50 (23.9)
Managing fatigue and debilitation 108 (51.7)
Regular contact with people with similar condition 65 (31.1)
Knowing whether what is happening to me is ‘normal’ 105 (50.2)
Diet and nutrition 28 (13.4)
Relationships with doctors 55 (26.3)
Support with identifying options and choices 42 (20.1)
Exercise and mobility 50 (23.9)
New research 95 (45.5)
Work and employment 5 (2.4)
Priorities specific to steroid treatmenta
Information on how to take steroids 56 (35.0)
Information the benefits and side effects of steroids 99 (61.9)
Information and support on how to manage steroid side effects 110 (68.8)
Information on how long I can expect to be on steroids 101 (63.1)
Information and support on how to taper the steroid dose. 145 (90.6)
a Only in those reporting Bbeing on and tapering off steroids^ as a priority
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health services and the third sector (especially those pro-
moting self-management strategies) will be key to provid-
ing comprehensive care to patients with a wide range of
conditions. For example, The King’s Fund’s number 1
priority for commissioners is to provide active support
for self-management [12] and the recent NHS BRealising
the Value^ programme [13] to support active patient self-
management has been in partnership with a number of
voluntary organisations. This type of partnership is likely
to continue. As such, evaluations of the services provided
by charities, such as PMRGCAuk, are relevant to clini-
cians so that they can ensure they signpost their patients
to relevant sources of support.
The administration of the survey via SurveyMonkey may
have impeded its completion by those without internet access,
or the Bknowhow^ to complete the survey. According to recent
data from the UK Office for National Statistics, which reports
that 90% of those aged 55 to 64 years, 78% of those aged 65 to
74 and 41% of those aged 75 or over have used the Internet in
the last 3 months [14], this is only likely to be a problem for
those people at the older end of the PMR/GCA spectrum [15].
However, due to financial restrictions, an online survey was
the only viable method of large-scale administration. To miti-
gate this problem as far as possible, the survey was also adver-
tised via in the Newswire magazine. Three people requested
and completed paper copies of the survey and some
Table 3 Services provided by
PMRGCAuk n (%)
Usefulness of support group (n (%) agree/strongly agree)
Helpful to meet other people with same condition 92 (96.8)
Guest speakers give useful information 56 (96.6)
Being part of group helps manage condition 81 (93.1)
Being part of group helps to feel more in control of treatment 76 (90.5)
Being part of group improves optimism for recovery 69 (80.2)
Group is well organised 82 (95.4)
Group members give personal support by phone/email 30 (73.2)
Usefulness of helpline (n (%) agree/strongly agree)
Number easy to find 49 (96.1)
Person who answered was helpful 49 (100.0)
Person who answered was good listener 46 (100.0)
Person who answered was knowledgeable 46 (97.9)
Received useful information during call 46 (97.9)
Good to talk to someone with experience of condition 45 (97.8)
Felt less anxious after call 39 (92.9)
Usefulness of web forum (n (%) agree/strongly agree)
Helpful to meet other people with same condition 98 (96.1)
Helps to feel less alone with condition 106 (95.5)
Helps to manage condition 102 (96.2)
Helps to feel more in control of treatment 101 (96.2)
Improves optimism for recovery 87 (86.1)
Reading other people’s experiences is reassuring 99 (90.0)
Reading other people’s experiences is confusing 27 (25.7)
Helpful to feel better equipped to ask right questions of doctor 102 (94.4)
Usefulness of website (n (%) agree/strongly agree)
Easy to find 161 (98.2)
Easy to navigate 150 (95.5)
Visually attractive 143 (98.0)
Appears up to date 146 (98.0)
Found what was looking for 138 (92.6)
Would go back again if needed more information 152 (95.0)
Would rather use a different site to get information 27 (19.2)
Website creates good impression of the charity 146 (97.3)
PMRGCAuk members’ magazine
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respondents stated in their responses to the open questions that
they had made the effort to get someone else to help them
complete the survey online.
PMRGCAuk is a UK-based charity and its provision is
therefore aimed at patients living in the UK, who will be most
likely be treated, at least in part, by the National Health
Service (NHS), unless they have chosen to seek exclusively
private treatment. This is relatively rare in the UK [16], as the
general practitioner still has a gatekeeper role and glucocorti-
coid prescriptions would still be available on the NHS.
However, there was evidence in the survey responses that at
least one person completed their survey from the USA. It
could be that more people than this were based outside the
UK. In addition, many of the results regarding what is impor-
tant to patients will be relevant to clinicians working outside
the UK and in other healthcare settings. For researchers, the
lack of an evidence base for elements of care that patients
highlighted as important is an international issue, although
potentially the importance of those aspects of care will differ.
There are few examples of charities and other patient orga-
nisations attempting to share their findings with the research
community in as direct a way as a publication such as this. It is
encouraging to see that the areas of highest concern to patients
align with those highlighted in recent publications from ex-
perts in the field as requiring further research (e.g. [17, 18]), as
this suggests that this is not a disconnect between theoretical
knowledge and clinical practice. However, this is also a major
concern, as it highlights gaps in the research field that are
perceived, not only by experts, but by patients. Even with
funding available to conduct research into these areas (e.g.
prognosis, ideal glucocorticoid regimens), which in itself
may be difficult to find in the current climate, recruitment to
studies and follow-up to fill these knowledge gaps may take
many years.
The majority of respondents thought information sur-
rounding glucocorticoid treatment was important to peo-
ple diagnosed with PMR and GCA. This is not to say that
this information is not currently provided, but specific
research evidence is lacking. Respondents reported that
information on taking, reducing and the side effects of
glucocorticoids was important. The current findings con-
cur with a recent qualitative study with general practi-
tioners [19] and highlight glucocorticoid management as
a major area in which the evidence base is lacking and
should be improved. For example, the EULAR/ACR
guidelines for the treatment of PMR recommend a starting
dose of 12.5 to 25 mg of prednisolone daily, and
individualised tapering of the dose [7]. This is largely
on the basis of expert consensus, rather than empirical
evidence, and there is very little to guide the clinician in
tapering the dose of an individual patient.
Other factors important to respondents were the outlook
for recovery and knowing whether what they were
experiencing was ‘normal’. It was also clear that many peo-
ple do not know about these conditions until they are diag-
nosed, which may make the process of receiving a diagnosis
more difficult and confusing for the patient [20]. While
some people reported that the local support groups and the
HealthUnlocked forum provided them with reassurance and
guidance, it is not scientific, generalizable data that are pro-
vided via these media, and reliance on anecdotes could
prove problematic. Indeed, around a quarter of respondents
repor ted that they found the discuss ions on the
HealthUnlocked forum confusing. What is required is an
evidence base of outcomes in PMR to guide health profes-
sionals when discussing prognosis with patients and from
which clinicians can provide the information that individual
patients want. In order to fully provide for this need, a qual-
itative study of patients’ needs in relation to information
provision is likely to be required.
The other major area of importance to respondents
was the management of fatigue. This is something that
is well-discussed in other rheumatological conditions
(e.g. rheumatoid arthritis), but less so in PMR or GCA.
Current EULAR/ACR guidelines conditionally recom-
mend Ban individualised exercise programme for PMR
patients aimed at the maintenance of muscle mass and
function, and reducing risk of falls…^ [7]. Such provi-
sion of physiotherapy, education relating to pacing or
similar graded exercise therapy for those with PMR or
GCA, may help patients to pro-actively manage fatigue
and debilitation. Further related research is overdue to
guide health professionals to select suitable treatments.
Table 4 Other aspects of the services provided by PMRGCAuk
N (%)
Why do not attend groupsa
No knowledge of them 14 (11.8)
Cannot make the meeting time 12 (10.1)
No group close enough 64 (53.8)
Have mobility problems 11 (9.2)
Do not want to attend a group 11 (9.2)
Other 7 (5.9)
Would attend telephone support group if available 81 (43.3)
What happened when you called the telephone helpline?
Answered straightaway 25 (12.0)
Left message on answering machine 18 (8.6)
Did not leave message on answering machine 5 (2.4)
Call returned promptly 15 (7.2)
Requested information pack during call 16 (7.7)
Received information pack after call 17 (8.1)
a Only in those people who do not currently attend a group
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Conclusions
Survey respondents highlighted areas of importance to
those with PMR and or GCA, emphasising the impor-
tance of holistic care and not just medical management,
although glucocorticoid treatment and tapering is a key
priority. The services provided by PMRGCAuk are gen-
erally well received and are important to their members.
Practice implications
The research community should be aware that for many
of the aspects of care for those with PMR and or GCA
that were highlighted by survey respondents, there is
little evidence base from which to provide information
or change in practice. This should be addressed as a
matter of urgency to improve the quality of life of those
diagnosed with these conditions. Specifically, evidence
is needed on optimal glucocorticoid regimens, progno-
sis, and the additional information and guidance that
patients require from their doctors and other health pro-
fessionals. Whilst such evidence is generated, clear and
relevant information to aid self-management should be
available to those who desire it.
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